- Follow Up for Breast Cancer Patients
- Helping Breast Cancer Patients Adhere to Hormone Therapy
- Opportunities Identified that Reduce Breast Cancer Screening Patient Burden
- Certain Birth Control Pills May Increase Cancer Risk
- Writing May Help Cancer Survivors
- New Method May Allow Breast Cancer Drug to Be Given Through Skin
- Findings Raise Hope of Preventing Breast Cancer with Statins
- Avoiding a Second Biopsy for Breast Cancer Patients
- African American Women with Breast Cancer Less Likely to Have Newer, Recommended Surgical Procedure
- Diabetes Drug May Also Protect Against Breast Cancer
Type 2 Diabetes Thiazolidinediones Double the Risk of Fractures
Thiazolidinediones are a class of drugs for type 2 diabetes that lower the blood sugar by increasing the sensitivity of cells to insulin.
Rosiglitazone and pioglitazone were associated with a significantly increased risk of fractures overall in the 10 randomized controlled trials.
Five randomized controlled trials showed a significantly increased risk of fractures among women.
The 2 observational studies demonstrated an increased risk of fractures associated with rosiglitazone and pioglitazone.
Bone mineral density in women exposed to thiazolidinediones was significantly reduced at the lumbar spine and hip in 2 randomized controlled trials.
The results of the research demonstrate long-term thiazolidinedione use doubles the risk of fractures among women with type 2 diabetes, without a significant increase in risk of fractures among men with type 2 diabetes.
Other contraindications to the use of thiazolidinediones include liver disease and heart failure.
1. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009 Jan 6;180(1):32-9. PMID: 19073651.
2. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007 Sep 12;298(10):1189-95. PMID: 17848653.
3. Singh S, Loke YK. The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf. 2008 Sep;7(5):579-85. PMID: 18759710.